Regado Biosciences Raises $40 Million
Regado Biosciences Inc., a Basking Ridge, N.J.-based developer of antithrombotic therapeutic aptamers with active control agents, has raised $40 million in Series D funding. Edmond de Rothschild Investment Partners led the round, and was joined by return backers Domain Associates, Quaker Bioventures, Aurora Funds and Caxton Advantage Life Sciences Fund. The company has now raised around $83 million since its 2002 inception.
17 December 2009•5 mins read
